Showing 3571-3580 of 4179 results for "".
- Dr. Reddy's Sernivo Officially Debuts at NYC Media Eventhttps://practicaldermatology.com/news/dr-reddys-sernivo-officially-debuts-at-nyc-event/2458473/Calling Sernivo (betamethasone dipropionate) Spray 0.05% a ‘trifecta’ for dermatologists who treat mild-to-moderate psoriasis, Josh Zeichner, MD, introduced members of the New York City media to the new spray-on steroid. “It is effe
- Study: 98% of Head Lice in at Least 42 States Now Resistant to Common OTC Treatmentshttps://practicaldermatology.com/news/98-of-head-lice-in-at-least-42-states-now-resistant-to-common-otc-treatments/2458480/Fully 98 percent of head lice in at least 42 states are resistant to various over-the-counter pyrethrins and pyrethroids including permethrin, which is the active ingredient in popular treatment formulations for pediculosis (Nix® (permethrin 1%), according to a study in t
- Melanoma Survival Rates Lower in Patients with Skin of Colorhttps://practicaldermatology.com/news/melanoma-survival-rates-lower-in-patients-with-skin-of-color/2458482/Although patients with skin of color are less likely to develop melanoma than caucasian patients, they have a higher rate of mortality from the disease, new research shows. Writing in the Jounral of the A
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
- Dermatologist Todd Schlesinger to Host Bellafill Discussion Fridayhttps://practicaldermatology.com/news/dermatologist-todd-schlesinger-to-host-bellafill-discussion-friday/2458484/Todd E. Schlesinger, MD, FAAD will host a program on behalf of Suneva, in which he will discuss Suneva's Bellafill® and other products. The event will be held Friday, July 29th, 2016 at 8pm at Towne Stove and Spirits, 900 Boylston Street, Boston. Those interested in atte
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien